KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Asset Writedowns and Impairment (2023 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Asset Writedowns and Impairment for 7 consecutive years, with $116.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Asset Writedowns and Impairment rose 684.45% year-over-year to $116.2 million, compared with a TTM value of $119.2 million through Dec 2025, changed N/A, and an annual FY2025 reading of $119.2 million, changed N/A over the prior year.
  • Asset Writedowns and Impairment was $116.2 million for Q4 2025 at Biomarin Pharmaceutical, up from $3.0 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $116.2 million in Q4 2025 and bottomed at -$19.9 million in Q4 2024.
  • Average Asset Writedowns and Impairment over 3 years is $22.5 million, with a median of $12.6 million recorded in 2023.
  • The sharpest move saw Asset Writedowns and Impairment crashed 176.62% in 2024, then surged 684.45% in 2025.
  • Year by year, Asset Writedowns and Impairment stood at $26.0 million in 2023, then plummeted by 176.62% to -$19.9 million in 2024, then soared by 684.45% to $116.2 million in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for BMRN at $116.2 million in Q4 2025, $3.0 million in Q1 2025, and -$19.9 million in Q4 2024.